Loading
A phase 2 trial of HLX10+chemo in small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.
A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC is a phase 2 interventional study registered as NCT06812260 by Shanghai Henlius Biotech, with 26 participants enrolled, started 2025-06-24 and due to reach its primary completion in 2026-10-22. Interventions recorded: HLX10+chemo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/